Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Recurrent Urinary Tract Infection Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

5 recruiting trials for Recurrent Urinary Tract Infection. Eligibility criteria explained in plain English.

TrialFinderData lists 5 Recurrent Urinary Tract Infection clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 4 is the largest group at 67% (2 studies); the largest phase groups are Phase 4: 2, Phase 2 / Phase 3: 1.

Research is led by Radboud University Medical Center (1), University of Texas Southwestern Medical Center (1), Hvidovre University Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Ialuril 50ml Prefill (device, 1 trial), followed by Nitrofurantoin, D-Mannose.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Track Recurrent Urinary Tract Infection trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 4NCT05652374

Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard...

The GT RACING is a study comparing the efficacy of HA-CS bladder installations with prophylactic antibiotics in the prevention of recurrent urinary tract infections (rUTI).

Sponsor: Radboud University Medical CenterEnrolling: 1003 locations
RECRUITINGNCT06940622

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection)...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 901 location
RECRUITINGNCT05553652

The Effect of ASTARTE™ on Recurrent Urinary Tract Infection

Investigate the effect of dietary supplements/probiotic ASTARTE™ ( L. crispatus, L. rhamnosus, L. jensenii, L. gasseri) on the microbiome composition in the intestine and vagina...

Sponsor: Hvidovre University HospitalEnrolling: 7201 location
RECRUITINGPhase 2 / Phase 3NCT06050148

Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections

This study investigates Faecal microbiota transplantation (FMT) in prevention of recurrent urinary tract infections (UTIs) caused either by sensitive E. coli or ESBL-E. coli.

Sponsor: Helsinki University Central HospitalEnrolling: 1001 location
RECRUITINGPhase 4NCT04807894

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the...

Sponsor: Maimonides Medical CenterEnrolling: 1001 location

Frequently Asked Questions

There are currently 5 clinical trials for Recurrent Urinary Tract Infection, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Recurrent Urinary Tract Infection, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Recurrent Urinary Tract Infection, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.